Gilead Sciences (NASDAQ: GILD) November option implied volatility is at 19, December is at 20; compared to its 52-week range of 20 to 43 into upcoming 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2019 in Orlando, Florida. GILD announced the acceptance of eight abstracts, including five oral presentations, for Yescarta® (axicabtagene ciloleucel) and other ongoing research from the companys chimeric antigen receptor (CAR) T cell therapy development program.